Improvement of Inflammatory Bowel Disease - Microbiome Inc. Secures Patent for Postbiotic "MB2"
- microbiomeint
- Nov 1, 2023
- 2 min read
Many modern individuals suffer from digestive disorders or inflammatory bowel disease due to irregular eating habits and frequent consumption of fast food, instant meals, processed foods, wheat-based products, and cold beverages. Symptoms often begin with mild issues such as belching, bloating, diarrhea, or constipation, but if left untreated, they can progress to dysbiosis, disrupt gut microbiota balance, and even lead to leaky gut syndrome, where blood contamination and serious illnesses may follow.
To address these problems, Microbiome Inc. announced that it has developed and patented MB2, a postbiotic with preventive, therapeutic, and improvement effects on inflammatory bowel disease. A company representative stated, "For patients suffering from inflammatory bowel disease, a new path has opened to manage the condition not with drugs, but with probiotics that are safe for the human body."
MB2 is a postbiotic derived from the heat-treated strain GLU70, known for its gluten-degrading properties, with enhanced efficacy for gut health. Its effects on the prevention, improvement, and treatment of inflammatory bowel disease were confirmed through studies that examined pathological changes in the intestinal tissues of gliadin-treated mice, levels of inflammatory cytokines, and expression of gliadin-related and inflammatory proteins.
In pathology tests, mice treated with gliadin showed severe villus inflammation, degeneration, and edema in intestinal tissue. By contrast, the MB2 treatment group showed inhibition of gliadin-induced intestinal damage. Measurements of inflammatory cytokines showed that MB2 reduced levels of TNF-α, an inflammatory cytokine, while increasing secretion of IL-10, an anti-inflammatory cytokine.
Further analysis of proteins related to leaky gut syndrome revealed that expression of zonulin and transglutaminase 2 (TGM2), which regulate tight junctions, and p65NF-κB, an inflammatory protein, were all significantly increased in the gliadin-only group. However, these levels were significantly reduced in the MB2-treated group.
A Microbiome Inc. representative added, "MB2 is already being produced and supplied. We expect it will help those who suffer from persistent bloating, diarrhea, and abdominal pain by restoring balance to the gut microbiota and improving inflammatory bowel conditions."
